Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash from Investing Activities (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Cash from Investing Activities data on record, last reported at $201.0 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities changed N/A year-over-year to $201.0 million; the TTM value through Dec 2025 reached $267.0 million, changed N/A, while the annual FY2025 figure was $66.0 million, 178.57% up from the prior year.
  • Cash from Investing Activities reached $201.0 million in Q4 2025 per RCUS's latest filing, up from $32.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $201.0 million in Q4 2025 and bottomed at -$268.0 million in Q1 2022.
  • Average Cash from Investing Activities over 5 years is -$7.4 million, with a median of $23.0 million recorded in 2022.
  • Peak YoY movement for Cash from Investing Activities: soared 13710.29% in 2021, then tumbled 7259.51% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at $18.8 million in 2021, then surged by 150.24% to $47.0 million in 2022, then tumbled by 40.43% to $28.0 million in 2023, then crashed by 203.57% to -$29.0 million in 2024, then surged by 793.1% to $201.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $201.0 million in Q4 2025, $32.0 million in Q1 2025, and -$29.0 million in Q3 2024.